Osservatorio Territoriale droga e tossicodipendenze. Il fenomeno delle dipendenze sul territorio della ASL MI 2. Anno 2007 - VIII Rapporto

Report on the state of legal and illegal substances use in the territory of the Local Healthcare Service-Mi 2, Province of Milan.L\u27analisi del fenomeno delle dipendenze nel territorio della Azienda Sanitaria Locale Provincia di Milano Due rappresenta l\u27ottavo rapporto pubblicato dall\u27OTDT del Dipartimento delle Dipendenze. Come avviene da anni, le analisi e gli approfondimenti contenuti contribuiranno in modo importante a rendere questo strumento utile alla programmazione territoriale di settore e al sistema di controllo di gestione aziendale. La maggior parte delle analisi epidemiologiche e tutti gli aspetti non convenzionali ed innovativi sono stati possibili grazie alla collaborazione con il CNR di Pisa, che ringrazio per l\u27impegno personale dei suoi esperti anche al di l? dei compiti definiti. Devo segnalare con piacere l\u27ampia partecipazione di operatori delle varie Unit? Operative del Dipartimento alla riflessione e poi alla stesura del rapporto. Non voglio entrare nel merito della illustrazione dei capitoli del rapporto e mi limito ad alcune considerazioni. Il rapporto, basato sui dati 2006 con alcune importanti escursioni nel 2007, appare veramente completo. Nell\u27invitare il lettore al diretto approfondimento dei suoi contenuti, mi limito a sottolineare alcuni elementi rappresentativi dell\u27evolvere del fenomeno sul territorio. Aumentano ancora i soggetti in cura alle UO SerT per uso di cocaina: tra i nuovi utenti, questi superano oramai il 50% e sopravanzano i nuovi utenti da eroina del 20% circa. L\u27impatto dei servizi alcologici sul territorio ? sempre pi? evidente, con un progressivo incremento dell\u27utenza in carico. Queste informazioni vanno per? lette alla luce delle stime di prevalenza, condotte anche quest\u27anno, che confermano una forte presenza di consumatori problematici di alcol, eroina e cocaina sul territorio della ASL MI2 e alla luce delle indagini di popolazione condotte dal CNR, qui pubblicate in forma di confronto tra la nostra zona e le tendenze regionali e nazionali. Anche queste indagini, ricche di informazioni e suggestioni, confermano che tra la popolazione generale e giovanile i consumi di sostanze sia legali che illegali sono diffusi e preoccupanti e meritano l\u27attenzione dei programmatori di politiche sanitarie e di educazione alla salute. Il lettore potr? farsi una idea della complessit? dei fenomeni di consumo, abuso e dipendenza, e delle loro relazioni intrinseche ed esterne. L\u27analisi ? organizzata dalla valutazione delle tendenze dei fenomeni sul territorio fino agli interventi di prevenzione cura e riabilitazione. Questo continuum rappresenta la chiave per affrontare con una visione realistica il "che fare". Il rapporto illustra chiaramente quanto "si faccia" nel territorio della ASL MI2 e richiama tutti i soggetti istituzionali a concorrere alla tutela dei cittadini con problemi di abuso e dipendenza da sostanze o comportamenti additivi. L\u27Osservatorio ha raggiunto un elevato standard di servizio utile per rappresentare la base per la redazione del Piano annuale di programmazione del Dipartimento recepito ampiamente nel fondamentale atto di programmazione e coordinamento dei servizi sanitari e socio sanitari curato dalla Azienda Sanitaria Locale. L\u27ampio spazio dedicato alle "regole" regionali e alla riorganizzazione della direzione sociale della ASL giunge in un momento delicato. Mentre scrivo inizia la fase applicativa della delibera di giunta regionale n. 5509 del 10 ottobre 2007 che accelera l\u27applicazione di alcuni principi cardine della filosofia regionale per il settore e i servizi accreditati. Ebbene ai professionisti dei servizi spetta attestare, con l\u27impegno e la competenza, il sostegno alle pi? moderne prassi di lettura dei fenomeni, il supporto operativo ad avanzate procedure istituzionali e l\u27intervento preventivo e clinico. Dott. Prof. Alfio Lucchini Direttore del Dipartimento tecnico funzionale delle Dipendenz

Osservatorio territoriale droga e tossicodipendenze. Il fenomeno delle dipendenze sul territorio della ASL MI 2. Anno 2008- IX Rapporto

Report on the state of legal and illegal substances use in the territory of the Local Healthcare Service-Mi 2, Province of MilanIl report analizza il fenomeno delle dipendenze nel territorio della ASL Milano 2. La descrizione del fenomeno si sviluppa intorno all\u27analisi degli indicatori individuati dall\u27Osservatorio Europeo delle Dipendenze di Lisbona (OEDT): 1-uso di sostanze nella popolazione generale (questo indicatore va a rilevare i comportamenti nei confronti di alcol e sostanze psicoattive da parte della popolazione generale); 2-prevalenza d\u27uso problematico delle sostanze psicoattive; 3-domanda di trattamento degli utilizzatori di sostanze; 4-mortalit? degli utilizzatori di sostanze; 5-malattie infettive. Altri due importanti indicatori che si stanno sviluppando, e che vengono qui illustrati, sono l\u27analisi delle Schede di Dimissione Ospedaliera (SDO) e gli indicatori relativi alle conseguenza sociali dell\u27uso di droghe (criminalit? droga correlata). Inoltre sono state applicate diverse metodologie standard di stima sia per quantificare la quota parte sconosciuta di utilizzatori di sostanze che non afferiscono ai servizi, sia per identificarne alcune caratteristiche

"Osservatorio territoriale droga e tossicodipendenze. Il fenomeno delle dipendenze nel territorio della ASL MI 2. Anno 2009- X Rapporto"

Report on the state of legal and illegal substances use in the territory of the Local Healthcare Service-MI 2, Province of Milan.Il Report analizza il fenomeno delle dipendenze nel territorio della ASL Milano 2. La descrizione del fenomeno si sviluppa intorno all\u27analisi degli indicatori individuati dall\u27Osservatorio Europeo delle Dipendenze di Lisbona (OEDT): 1-uso di sostanze nella popolazione generale (questo indicatore va a rilevare i comportamenti nei confronti di alcol e sostanze psicoattive da parte della popolazione generale); 2-prevalenza d\u27uso problematico delle sostanze psicoattive; 3-domanda di trattamento degli utilizzatori di sostanze; 4-mortalit? degli utilizzatori di sostanze; 5-malattie infettive. Altri due importanti indicatori che si stanno sviluppando, e che vengono qui illustrati, sono l\u27analisi delle Schede di Dimissione Ospedaliera (SDO) e gli indicatori relativi alle conseguenza sociali dell\u27uso di droghe (criminalit? droga correlata). Inoltre sono state applicate diverse metodologie standard di stima sia per quantificare la quota parte sconosciuta di utilizzatori di sostanze che non afferiscono ai servizi, sia per identificarne alcune caratteristiche

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18-4.74, p = 0.015) with increased risk of severe COVID-19. Recent use (<1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20-12.53, p = 0.001). Results were confirmed by the PS-weighted analysis and by all the sensitivity analyses. Interpretation: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID-19 pandemic persists

COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Background and objectives: It is unclear how multiple sclerosis (MS) affects the severity of COVID-19. The aim of this study is to compare COVID-19-related outcomes collected in an Italian cohort of patients with MS with the outcomes expected in the age- and sex-matched Italian population. Methods: Hospitalization, intensive care unit (ICU) admission, and death after COVID-19 diagnosis of 1,362 patients with MS were compared with the age- and sex-matched Italian population in a retrospective observational case-cohort study with population-based control. The observed vs the expected events were compared in the whole MS cohort and in different subgroups (higher risk: Expanded Disability Status Scale [EDSS] score > 3 or at least 1 comorbidity, lower risk: EDSS score ≤ 3 and no comorbidities) by the χ2 test, and the risk excess was quantified by risk ratios (RRs). Results: The risk of severe events was about twice the risk in the age- and sex-matched Italian population: RR = 2.12 for hospitalization (p < 0.001), RR = 2.19 for ICU admission (p < 0.001), and RR = 2.43 for death (p < 0.001). The excess of risk was confined to the higher-risk group (n = 553). In lower-risk patients (n = 809), the rate of events was close to that of the Italian age- and sex-matched population (RR = 1.12 for hospitalization, RR = 1.52 for ICU admission, and RR = 1.19 for death). In the lower-risk group, an increased hospitalization risk was detected in patients on anti-CD20 (RR = 3.03, p = 0.005), whereas a decrease was detected in patients on interferon (0 observed vs 4 expected events, p = 0.04). Discussion: Overall, the MS cohort had a risk of severe events that is twice the risk than the age- and sex-matched Italian population. This excess of risk is mainly explained by the EDSS score and comorbidities, whereas a residual increase of hospitalization risk was observed in patients on anti-CD20 therapies and a decrease in people on interferon

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon

Differential cross section measurements for the production of a W boson in association with jets in proton–proton collisions at √s = 7 TeV

Measurements are reported of differential cross sections for the production of a W boson, which decays into a muon and a neutrino, in association with jets, as a function of several variables, including the transverse momenta (pT) and pseudorapidities of the four leading jets, the scalar sum of jet transverse momenta (HT), and the difference in azimuthal angle between the directions of each jet and the muon. The data sample of pp collisions at a centre-of-mass energy of 7 TeV was collected with the CMS detector at the LHC and corresponds to an integrated luminosity of 5.0 fb[superscript −1]. The measured cross sections are compared to predictions from Monte Carlo generators, MadGraph + pythia and sherpa, and to next-to-leading-order calculations from BlackHat + sherpa. The differential cross sections are found to be in agreement with the predictions, apart from the pT distributions of the leading jets at high pT values, the distributions of the HT at high-HT and low jet multiplicity, and the distribution of the difference in azimuthal angle between the leading jet and the muon at low values.United States. Dept. of EnergyNational Science Foundation (U.S.)Alfred P. Sloan Foundatio

Optimasi Portofolio Resiko Menggunakan Model Markowitz MVO Dikaitkan dengan Keterbatasan Manusia dalam Memprediksi Masa Depan dalam Perspektif Al-Qur`an

Risk portfolio on modern finance has become increasingly technical, requiring the use of sophisticated mathematical tools in both research and practice. Since companies cannot insure themselves completely against risk, as human incompetence in predicting the future precisely that written in Al-Quran surah Luqman verse 34, they have to manage it to yield an optimal portfolio. The objective here is to minimize the variance among all portfolios, or alternatively, to maximize expected return among all portfolios that has at least a certain expected return. Furthermore, this study focuses on optimizing risk portfolio so called Markowitz MVO (Mean-Variance Optimization). Some theoretical frameworks for analysis are arithmetic mean, geometric mean, variance, covariance, linear programming, and quadratic programming. Moreover, finding a minimum variance portfolio produces a convex quadratic programming, that is minimizing the objective function ðð¥with constraintsð ð 𥠥 ðandð´ð¥ = ð. The outcome of this research is the solution of optimal risk portofolio in some investments that could be finished smoothly using MATLAB R2007b software together with its graphic analysis

Juxtaposing BTE and ATE – on the role of the European insurance industry in funding civil litigation

One of the ways in which legal services are financed, and indeed shaped, is through private insurance arrangement. Two contrasting types of legal expenses insurance contracts (LEI) seem to dominate in Europe: before the event (BTE) and after the event (ATE) legal expenses insurance. Notwithstanding institutional differences between different legal systems, BTE and ATE insurance arrangements may be instrumental if government policy is geared towards strengthening a market-oriented system of financing access to justice for individuals and business. At the same time, emphasizing the role of a private industry as a keeper of the gates to justice raises issues of accountability and transparency, not readily reconcilable with demands of competition. Moreover, multiple actors (clients, lawyers, courts, insurers) are involved, causing behavioural dynamics which are not easily predicted or influenced. Against this background, this paper looks into BTE and ATE arrangements by analysing the particularities of BTE and ATE arrangements currently available in some European jurisdictions and by painting a picture of their respective markets and legal contexts. This allows for some reflection on the performance of BTE and ATE providers as both financiers and keepers. Two issues emerge from the analysis that are worthy of some further reflection. Firstly, there is the problematic long-term sustainability of some ATE products. Secondly, the challenges faced by policymakers that would like to nudge consumers into voluntarily taking out BTE LEI